welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
study id #: NCT04254172
condition: Duchenne Muscular Dystrophy (DMD)
The purpose of this low interventional study is to collect data on everyday movement in boys with Duchenne muscular dystrophy (DMD) using wearable activity sensors. The activity sensors could provide useful information beyond what is currently collected by functional (movement, strength) assessments in clinic. This information can help with the understanding of the impact of DMD, and perhaps with how possible treatments can affect this impact.
intervention: Activity Monitor
mechanism of action: No pharmaceutical intervention
last updated: March 01, 2020
start date: February 19, 2020
estimated completion: August 12, 2021
phase of development: N/A
size / enrollment: 20
- Mean change from baseline and variability of activity measures [ Time Frame: baseline, 3, 6, 9, and 12 months ]
- Mean change from baseline in functional assessment scores obtained in the clinic [ Time Frame: baseline, 3, 6, 9, and 12 months ]
- Comparison of mean changes from baseline and correlation coefficient between activity monitoring data and functional data obtained in clinic [ Time Frame: baseline, 3, 6, 9, and 12 months ]
• Eligible Sexes: male
• Body weight between 15 and 50 kg
• Receipt of glucocorticoids for 6 months and a stable daily dose for at least 3 months prior to study entry
• Ability to rise from floor within seven (7) seconds and ability to walk
• Current exposure to systemic immunosuppressant agents other than glucocorticoids.
• Prior exposure to any gene therapy agent, including exon-skipping and missense agents.
• Exposure to other investigational drugs within 30 days or 5 half-lives, whichever is longer.
• Any injury which may impact functional testing per investigator's judgement. Previous injuries must be fully healed prior to consenting. Prior lower limb fractures must be fully healed and at least 3 months from injury date at screening.
• Any planned surgeries which may impact physical activity and performance.
• Presence or history of musculoskeletal or neurological disease in addition to DMD.
• Any known allergies or skin reactions to stainless steel, versaflex, and silicon that may cause possible discomfort by wearable sensors.
• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, cancer, autoimmune or allergic disease that may interfere with the study conduct as per investigator's judgment, excluding untreated, asymptomatic, seasonal allergies at time of screening.
• Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are Pfizer employees, including their family members, directly involved in the conduct of the study.
Cardiac management of the patient with Duchenne muscular dystrophyDuchenne muscular dystrophy (DMD) result...
The importance of wheelchair accessibility on beachesImagine this; you’re on your way to th...
User-centred Assistive System for Arm Functions in Neuromuscular SubjectsRestore a lost function is a special exp...
Use of Dynamic Arm Supports to Promote Activities of Daily Living in Individuals With DMDThis study is a longitudinal, randomized...
Finding clinical meaning in patient-reported functional health: development of the Duchenne muscular dystrophy lifet...Person-reported outcome (PRO) measures f...
Brothers with rare condition painting postcards to fund custom vehicleTwo brothers in Cambridge with a rare ge...
Seismic Announces Strategic Partnerships With Solid BiosciencesSeismic, an apparel company making cloth...